Compositions for diagnosis, prevention, or treatment of fatty liver disease
AssigneesHysensbio, Seoul National University R&Db Foundation
InventorsJoo Cheol Park, Dong Seol Lee, Geumbit Hwang
Life of this patent
Estimating the term…
Abstract
CPNE7 protein or a nucleotide encoding for CPNE7 protein, or compositions containing the CPNE7 or the nucleotide and their uses are disclosed. The protein, nucleotide, or composition is useful for preventing or treating fatty liver disease. The CPEN7 protein regulates the expression of the SREBF1 (SREBP1) gene or a gene encoding the same. The composition can be a pharmaceutical composition or a quasi-drug composition, a health functional food, or a dietary supplement, which is suitable for preventing or alleviating fatty liver disease.
Claims9
A method of treating non-alcoholic fatty liver disease of a subject in need thereof, comprising:
- administering to the subject an effective amount of a composition consisting of (a) an active component and (b) a pharmaceutically acceptable carrier, an excipient, or a diluent, wherein the active component consists of an unmodified full length CPNE7 protein or a fragment thereof or a gene encoding the unmodified CPNE7 protein or a fragment thereof, wherein said gene is contained in an expression vector and is operably linked,
- wherein the unmodified full length CPNE7 protein or a fragment thereof comprises two N-terminal C2 domains and one Von Willebrand Factor A domain, and
- wherein the subject has a non-alcoholic fatty liver in which intrahepatic fat deposition is 5% or more of a weight of liver of the subject.
Dependencies are inferred from the claim text.